Century Therapeutics, Inc. (IPSC)

3.0000 -0.0100 (-0.33%) At close: 04:00PM EDT

Century Therapeutics, Inc.

25 North 38th Street
11th Floor
Philadelphia, PA 19104
United States
267 817 5790
https://www.centurytx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 152

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Brent Pfeiffenberger M.B.A., Pharm.D.	CEO & Director	274.06k	N/A	N/A
Dr. Adrienne Farid Ph.D.	COO & Head of Early Development	670.29k	N/A	1962
Dr. Gregory Russotti Ph.D.	Chief Technology & Manufacturing Officer	852.56k	N/A	1967
Mr. Douglas Carr CPA	Interim Principal Financial Officer, Senior VP of Finance & Operations and Secretary	N/A	N/A	N/A
Mr. Kenneth J. Dow J.D.	Senior VP of General Counsel	N/A	N/A	N/A
Dr. Shane Williams Ph.D.	Chief People Officer	N/A	N/A	N/A
Dr. Hyam I. Levitsky M.D.	President of Research & Development	502.12k	N/A	1958
Michael Naso Ph.D.	Senior VP of Cell Engineering	N/A	N/A	N/A
Dr. Nick Trede M.D., Ph.D.	Senior VP & Head of Clinical Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Corporate governance

Century Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.